Therapeutic antibodies have undergone a significant evolution, with an increasing variety of monoclonal antibodies (mAbs) entering clinical and commercial phases, including non-traditional formats like fragments and multispecifics. This diversification poses new challenges for manufacturers in the purification process, necessitating a departure from the conventional one-size-fits-all chromatography approach. Niklas Jungnelius, a process modeling leader at Cytiva, highlighted the evolving landscape of therapeutic antibodies during a session at the BioProcess International Conference in Boston.
The complexity of antibody formats and the pursuit of objectives such as cost reduction and sustainability are driving the shift towards optimized chromatographic solutions. The need for more efficient manufacturing processes has led to the optimization of chromatography resins for improved economy, productivity, and environmental impact. This optimization journey involves addressing diverse affinities required by different antibody molecules and adapting to varying processing conditions, including pH sensitivity.
Challenges in Resin Selection and Capture-Process Optimization
Selecting the appropriate capture process involves balancing multiple factors, with resin attributes like capacity, flow properties, and durability playing pivotal roles in determining process outcomes. Various intensification technologies place different demands on the resin, necessitating careful consideration during selection. For instance, continuous chromatography linked to perfusion bioreactors demands highly durable resins capable of withstanding extensive cleaning cycles, while high-titer fed-batch processes benefit from resins offering a robust balance of capacity and flow performance.
Process modeling has emerged as a valuable tool in guiding decision-making processes. By modeling the process across different applicable scales, manufacturers can navigate challenges like flow-velocity restrictions that may vary significantly between small and large column diameters. The diversification of antibody formats introduces new purification hurdles, such as addressing aggregation tendencies and the removal of mispaired chains, which can be particularly challenging.
Strategies for Enhancing Purity, Yield, and Productivity
Standard mAbs typically undergo protein A capture combined with optimized washing steps to achieve adequate purity levels. Yield enhancements often stem from fine-tuning elution pH and load, while productivity gains can be realized through incremental and advanced strategies. Simple yet impactful improvements, such as utilizing high-capacity resins with optimal flow properties or implementing more refined protocols, can yield significant benefits.
Rapid-cycling chromatography, which reduces residence times and resin consumption, presents a promising approach for enhancing productivity. Advanced techniques like periodic counter-current chromatography (PCC) offer avenues to maximize resin utilization. In the case of more intricate antibody formats, a diverse range of affinity resins is essential to achieve high purity and yield, with further intensification possible through protocol optimization and advanced chromatography technologies.
Future of Antibody Purification Strategies
As antibody therapies progress, purification strategies must evolve to support these advancements. The transition towards tailored chromatography solutions underscores the industry’s commitment to efficiency, sustainability, and quality. The future lies in scalable, adaptable resin toolboxes that can optimize both individual processes and platform strategies to meet the diverse needs of modern antibody pipelines.
In conclusion, optimizing chromatography for therapeutic antibody processing is not just about enhancing efficiency; it is a strategic imperative driven by the need for tailored solutions in a rapidly evolving bioprocessing landscape. By embracing advanced technologies, leveraging diverse affinity resins, and integrating robust process modeling, manufacturers can navigate the complexities of antibody purification with greater precision and efficacy. This transformative journey towards optimized chromatography stands as a testament to the industry’s dedication to innovation and excellence in bioprocess optimization.
Key Takeaways:
– The evolving landscape of therapeutic antibodies demands tailored chromatography solutions.
– Resin selection and process modeling are crucial for optimizing capture processes.
– Strategies for enhancing purity, yield, and productivity include protocol optimization and advanced chromatography techniques.
– The future of antibody purification lies in scalable, adaptable resin toolboxes tailored to individual processes and platform strategies.
Tags: biotech, chromatography, bioprocess, monoclonal antibodies
Read more on genengnews.com